Description

AXENTRI 150 MG (1X60)

Indications

AXENTRI (maraviroc) is indicated for the treatment of adults and pediatric patients aged 2 years and older who are infected with CCR5-tropic HIV-1. It is used in combination with other antiretroviral agents to achieve optimal viral suppression. The drug is particularly beneficial for patients who have not previously received antiretroviral therapy or for those who have experienced treatment failure with other regimens. AXENTRI is not effective against CXCR4-tropic HIV-1 or dual-tropic HIV-1 strains.

Mechanism of Action

AXENTRI works as a CCR5 antagonist, which means it selectively binds to the CCR5 co-receptor on the surface of CD4 cells. By blocking this co-receptor, AXENTRI prevents the entry of CCR5-tropic HIV-1 into these cells. This inhibition of viral entry is crucial because it stops the virus from replicating and spreading within the host’s immune system. The effectiveness of AXENTRI is contingent upon the presence of CCR5-tropic HIV-1, making it essential to perform a tropism test prior to initiating therapy.

Pharmacological Properties

AXENTRI is characterized by its unique pharmacokinetic profile. The drug is well-absorbed following oral administration, with peak plasma concentrations occurring approximately 0.5 to 4 hours post-dose. It has a bioavailability of around 33% when taken with food. Maraviroc is extensively metabolized in the liver primarily by the cytochrome P450 3A4 enzyme, resulting in several metabolites, although the parent compound is the most active. The elimination half-life of AXENTRI is approximately 14 to 18 hours, allowing for once-daily dosing in most patients.

Contraindications

AXENTRI is contraindicated in patients with a known hypersensitivity to maraviroc or any of the inactive ingredients in the formulation. Additionally, it should not be used in patients with severe renal impairment (creatinine clearance less than 30 mL/min) unless under careful medical supervision. The use of AXENTRI is also contraindicated in individuals with active hepatitis B or C infections, as well as in those who are co-infected with other viral pathogens that may complicate treatment.

Side Effects

Common side effects of AXENTRI include, but are not limited to, cough, fever, rash, abdominal pain, and musculoskeletal pain. Serious adverse effects can occur, including hepatotoxicity, cardiovascular events, and hypersensitivity reactions. Patients should be monitored for signs of liver dysfunction, as elevations in liver enzymes have been reported. Additionally, there is a risk of developing infections due to the immunosuppressive effects of HIV and the potential for drug interactions that may exacerbate these issues.

Dosage and Administration

The recommended dosage of AXENTRI for adults and pediatric patients aged 12 years and older is 300 mg twice daily, while for those aged 2 to 11 years, the dosage is weight-based. It is important to assess the patient’s renal function before initiating therapy, as dose adjustments may be necessary for patients with renal impairment. AXENTRI can be taken with or without food, but consistent administration with respect to meals is advised to maintain stable drug levels in the bloodstream.

Interactions

AXENTRI is subject to numerous drug interactions due to its metabolism by the cytochrome P450 3A4 enzyme. Co-administration with strong CYP3A4 inducers (e.g., rifampin, St. John’s wort) can decrease maraviroc levels, potentially leading to therapeutic failure. Conversely, strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) can increase maraviroc levels, raising the risk of toxicity. Patients should be carefully evaluated for potential drug interactions before starting AXENTRI, and appropriate adjustments to therapy should be made as necessary.

Precautions

Prior to initiating treatment with AXENTRI, it is crucial to perform a tropism test to confirm the presence of CCR5-tropic HIV-1. Patients should be monitored for signs of infection, liver dysfunction, and any other adverse effects throughout the course of treatment. Special caution should be exercised in patients with a history of cardiovascular disease, as maraviroc has been associated with an increased risk of cardiovascular events. Pregnant and breastfeeding women should discuss the risks and benefits of therapy with their healthcare provider, as the safety of AXENTRI in these populations has not been fully established.

Clinical Studies

Clinical trials have demonstrated the efficacy of AXENTRI in reducing viral load and increasing CD4 cell counts in patients with CCR5-tropic HIV-1. In pivotal studies, patients receiving AXENTRI in combination with other antiretroviral agents achieved significant improvements in virologic outcomes compared to those receiving placebo. Long-term studies have also indicated that AXENTRI is generally well-tolerated, with a safety profile consistent with that observed in earlier trials. Ongoing research continues to evaluate the long-term effects of maraviroc on patient outcomes, particularly in diverse populations and in combination with emerging therapies.

Conclusion

AXENTRI 150 mg (1×60) is a valuable addition to the armamentarium against HIV-1, particularly for patients with CCR5-tropic strains. Its unique mechanism of action as a CCR5 antagonist provides an alternative therapeutic option for individuals who may not respond to traditional antiretroviral therapies. However, careful patient selection, monitoring for side effects, and awareness of potential drug interactions are essential for optimizing treatment outcomes. As with all medications, the use of AXENTRI should be part of a comprehensive HIV management plan that includes regular follow-up and adherence support.